Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC

Oncologist

Volumn 11, Issue 3, 2006, Pages 274-284

  Maione, Paolo ^a   Gridelli, Cesare ^a   Troiani, Teresa ^b   Ciardiello, Fortunato ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Bevacizumab; Erlotinib; Multitargeted therapy; NSCLC; ZD6474

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AZD 2171; BEVACIZUMAB; BEXAROTENE; BIBF 1120; CARBOPLATIN; CELECOXIB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; RAPAMYCIN; SORAFENIB; TIPIFARNIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DESQUAMATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FLUSHING; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIVER TOXICITY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOLID TUMOR; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645051467     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-3-274     Document Type: Article

References (52)

1. Jemal A, Murray T, Samuels A et al. Cancer Statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Parkin DM, Bray F, Ferlay J et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
3. Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253.
4. Hotta K, Matsuo K, Ueoka H et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22:3860-3867.
5. Curran WJ Jr, Scott CB, Langer CJ et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:621a.
6. Hotta K, Matsuo K, Ueoka H et al. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 2004;15:1782-1789.
7. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-2246.
8. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
9. Thatcher T, Chang A, Parikh P et al. ISEL: a phase III survival study comparing gefitinib (Iressa) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced NSCLC (NSCLC) who had received one or two prior chemotherapy regimens. Lung Cancer 2005;49(suppl 2):S4.
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non small cell lung cancer. N Engl J Med 2005;353:123-132.
11. Sandler AB, Gray R, Brahmer J et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc Am Soc Clin Oncol 2005;23:1090s.
12. Tortora G, Caputo R, Damiano V et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003;9:1566-1572.
13. Tortora G, Caputo R, Damiano V et al. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic and antiangiogenic activity. Clin Cancer Res 2003;9:866-871.
14. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
15. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
16. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-794.
17. Gatzemeier U, Pluzanska A, Szczesna A et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:617a.
18. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
19. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
20. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002;29(suppl 14):38-44.
21. Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-1556.
22. Hirata A, Ogawa S, Kometani T et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-2560.
23. Ciardiello F, Bianco R, Damiano V et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-3747.
24. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-smallcell lung cancer. J Clin Oncol 2005;23:2544-2555.
25. Tsao AS, Herbst R, Sandler A et al. Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: correlation of treatment response with mutations of the EGFR tyrosine kinase gene. Proc Am Soc Clin Oncol 2005;23:643s.
26. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
27. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
28. Ma CX, Croghan G, Reid J et al. A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2005;23:192s.
29. Dragnev KH, Petty WJ, Shah S et al. A phase I trial of erlotinib and bexarotene as a targeted combination therapy for aerodigestive tract cancers. Proc Am Soc Clin Oncol 2005;23:643s.
30. Sun SY, Rosenberg LM, Wang X et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-7058.
31. Milton DT, Kris MG, Azzoli CG et al. Phase I/II trial of gefitinib and RAD001 (everolimus) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2005;23:646s.
32. Krysan K, Reckamp KL, Dolwadi H et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signalling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005;65:6275-6281.
33. Reckamp KL, Dubinett SM, Krysan K et al. A phase I trial of targeted COX-2 and EGFR TK inhibition in advanced NSCLC. Proc Am Soc Clin Oncol 2005;23:648s.
34. van Cruijsen, Voest EE, van Herpen CM et al. Phase I clinical evaluation of AZD2171 in combination with gefitinib in patients with advanced tumors. Proc Am Soc Clin Oncol 2005;23:199s.
35. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4646-4655.
36. Carlomagno F, Vitagliano D, Guida T et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-7290.
37. Ciardiello F, Caputo R, Bianco R et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-1465.
38. Wu W, Isobe T, Itasaka S et al. ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer. Proc Am Assoc Cancer Res 2004;45:1051.
39. Williams KJ, Telfer BA, Stratford IJ et al. Schedule-dependent effects of ZD6474, a potent inhibitor of VEGF signaling, combined with radiotherapy in a lung tumor xenograft model. Clin Cancer Res 2003;9:6141S.
40. Hurwitz H, Holden SN, Eckhardt SG et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signalling, in patients with solid tumors. Proc Am Soc Clin Oncol 2002;21:82a.
41. Minami H, Ebi H, Tahara M et al. A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 2003;22:194a.
42. Natale R, Bodkin D, Govindan R et al. A comparison of the antitumor efficacy of ZD 6474 and gefitinib (Iressa) in patients with NSCLC: results of a randomised, double blind, phase II study. Lung Cancer 2005;49(suppl 2):S37.
43. Herbst R, Johnson B, Rowbottom J et al. ZD 6474 plus docetaxel in patients with previously treated NSCLC: results of a randomised, placebo-controlled phase II trial. Lung Cancer 2005;49(suppl 2):S35.
44. Ciardiello F, Bianco R, Caputo R et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004;10:784-793.
45. Taguchi F, Koh Y, Koizumi F et al. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer Sci 2004;95:984-989.
46. Tuccillo C, Romano M, Troiani T et al. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin Cancer Res 2005;11:1268-1276.
47. Baselga J, Rojo F, Dumez H et al. Phase I study of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: a pharmacokinetic-pharmacodynamic study to identify the optimal therapeutic dose regimen. Proc Am Soc Clin Oncol 2005;23:198s.
48. Martinelli E, Takimoto CH, van Oosterom AT et al. AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: preliminary phase I results. Proc Am Soc Clin Oncol 2005;23:201s.
49. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
50. Minami H, Kawada K, Ebi H et al. A phase I study of BAY 43-9006, a dual inhibitor of Raf and VEGFR kinases, in Japanese patients with solid cancers. Proc Am Soc Clin Oncol 2005;23:206s.
51. Adjei AA, Mandrekar S, Marks RS et al. A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer. Proc Am Soc Clin Oncol 2005;23:206s.
52. Lee CP, Attard G, Poupard L et al. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2005;23:205s.